SV

Street Verdict

Analyst Scorecard

TORNTPHARM · NSE

Torrent Pharmaceuticals Limited

₹4,689.5

+1.70% (+₹78.5)

Prev. close

₹4,611

Volume

2,00,042

Delivery %

61.1%

As of

20 Nov 2026

Price history

₹4,689.5-₹281.5 (-5.66%) · 3M
18 Aug 2026 → 20 Nov 2026
4,6004,7004,8004,9005,00018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts are split

2 analyst stances · last 90 days · one per analyst

Trackable

2 · 1 bull / 0 neutral / 1 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 50% (1)Neutral 0% (0)Bearish 50% (1)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 5 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, ProZuca, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Sanjay Gupta

Headquarters

Ahmedabad

Employees

18,258

Key stats

Market cap

₹1.79 L Cr

P/E ratio (TTM)

79.4

Dividend yield

0.82%

EPS (TTM)

₹59.20

Beta (1Y · daily vs NIFTY 50)

0.30

Beta (5Y · monthly vs NIFTY 50)

0.70

Shares float

14.67 Cr

EPS · quarter ended Sept 2026

₹14.05

Financial Performance

01 · Financials

0 Cr5000 Cr10000 Cr15000 Cr₹0%5%10%15%20%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

0255075₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

0102030₹-100%0%100%200%18 Mar 2015 Feb 2117 Jun 2102 Feb 2203 Feb 2323 Jun 2312 Feb 2421 Jun 2431 Jan 2520 Jun 2518 Feb 2629 May 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-50%0%50%100%FY21FY22FY23FY24FY25FY26
SalesFixed assetsReceivables (trade + unbilled)Inventory

05 · Capital Structure & Asset Utilization

0 Cr20000 Cr40000 Cr60000 Cr₹0×0.5×1×1.5×2×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr20000 Cr40000 Cr60000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

0 Cr5000 Cr10000 Cr15000 Cr20000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹8,005.00 Cr₹8,508.00 Cr₹9,620.00 Cr₹10,728.00 Cr₹11,516.00 Cr₹13,980.00 Cr
EBITDA
₹2,542.00 Cr₹2,143.00 Cr₹2,887.00 Cr₹3,500.04 Cr₹3,720.00 Cr₹4,376.00 Cr
₹1,252.00 Cr₹777.00 Cr₹1,245.00 Cr₹1,656.00 Cr₹1,911.00 Cr₹2,163.00 Cr
Diluted EPS
₹36.99₹22.97₹36.79₹48.94₹56.47₹63.92

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹14,074.65 Cr₹13,099.84 Cr₹15,011.85 Cr₹15,061.00 Cr₹14,990.00 Cr₹44,312.00 Cr
₹4,874.13 Cr₹4,069.65 Cr₹5,368.56 Cr₹4,021.94 Cr₹3,202.32 Cr₹15,025.50 Cr
Stockholders' equity
₹5,837.17 Cr₹5,952.95 Cr₹6,198.07 Cr₹6,856.00 Cr₹7,591.00 Cr₹8,389.00 Cr

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹2,011.00 Cr₹1,803.00 Cr₹2,368.00 Cr₹3,266.00 Cr₹2,585.00 Cr₹3,023.00 Cr
Investing cash flow
₹-449.00 Cr₹-198.00 Cr₹-2,415.31 Cr₹-168.00 Cr₹-540.00 Cr₹-12,713.00 Cr
₹-1,656.00 Cr₹-1,781.00 Cr₹77.00 Cr₹-2,779.00 Cr₹-2,298.00 Cr₹10,151.00 Cr
Capital expenditure
₹-335.00 Cr₹-203.00 Cr₹-574.00 Cr₹-433.00 Cr₹-611.00 Cr₹-677.00 Cr
End cash position
₹572.56 Cr₹398.40 Cr₹508.53 Cr₹835.00 Cr₹573.00 Cr₹1,117.00 Cr

Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21–Sep 24(14Q)Dec 24–Jun 26(7Q)Jul 26
Promoter71.25%68.31%60.78%
Public28.75%31.69%39.22%
Employee trusts0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Lupin Limited₹92,244.53 Cr₹2,008.616.74.1123.8%0.29+23.9%+0.6%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

TORNTPHARM

Results: Alembic Pharmaceuticals Limited Beat Earnings Expectations And Analysts Now Have New Forecasts

Simply Wall St · 16 days ago

TORNTPHARM

Emcure Pharmaceuticals Limited Beat Revenue Forecasts By 6.4%: Here's What Analysts Are Forecasting Next

Simply Wall St · 17 days ago